| 4.04 0.12 (3.06%) | 01-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.05  |
1-year : | 7.27 |
| Resists | First : | 5.18 |
Second : | 6.23 |
| Pivot price | 3.93 |
|||
| Supports | First : | 3.5 | Second : | 2.91 |
| MAs | MA(5) : | 3.99 |
MA(20) : | 4.13 |
| MA(100) : | 7.11 |
MA(250) : | 23.77 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 49.8 |
D(3) : | 40.8 |
| RSI | RSI(14): 43.7 |
|||
| 52-week | High : | 945 | Low : | 3.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ENVB ] has closed below upper band by 33.7%. Bollinger Bands are 84% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.18 - 4.2 | 4.2 - 4.22 |
| Low: | 3.74 - 3.77 | 3.77 - 3.8 |
| Close: | 4 - 4.04 | 4.04 - 4.08 |
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Mon, 29 Dec 2025
Enveric Biosciences (ENVB) Secures Patent for Novel Mental Healt - GuruFocus
Mon, 29 Dec 2025
Enveric Biosciences Announces Patent Issuance - Business Wire
Fri, 12 Dec 2025
Enveric Biosciences raises $3.1 million through warrant exercise - Investing.com
Thu, 11 Dec 2025
Enveric Biosciences secures $3.1 million through warrant exercise - Investing.com
Thu, 11 Dec 2025
Enveric Biosciences shareholders approve stock issuance and share increase proposals - Investing.com
Thu, 11 Dec 2025
Enveric Biosciences skyrockets on patent allowance for psychedelic-inspired molecules - Mugglehead Magazine
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 532530 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 44 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -133.3 % |
| Return on Equity (ttm) | -262.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.27931e+007 |
| Qtrly Earnings Growth | 390.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | 4.03 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.17 |
| Dividend | 0 |
| Forward Dividend | 62720 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|